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Abstract
Aims—Repair of abdominal aortic aneurysms (AAA) decreases the incidence of rupture and 
death. In cancer patients, sarcopenia has been associated with increased surgical complications and 
mortality. The impact of sarcopenia on survival after AAA repair has yet to be described.
Methods and Results—Patient demographic, laboratory, body composition measurements and 
survival data were obtained from patients undergoing AAA repair at the Indiana University 
medical campus over a 5-year period. Univariate and multivariate analyses were performed to 
identify factors associated with overall survival. Overall, 58.2% presented with sarcopenia. 
Sarcopenic patients were older (71.8±8.3 versus 66.8±8.1 years; p<0.001), had lower body mass 
index (BMI) (26.3±5.2 versus 31.5±5.9 kg/m2; p<0.001), higher rates of myosteatosis (84.4% 
versus 52.%; p<0.001), greater AAA diameter (60.6±14.0 versus 57.8±11.7 mm; p=0.016), higher 
Charlson Comorbidity Index (CCI) (32.3% versus 25.1% ≥6; p=0.034), and increased rates of 
rupture (8.2% versus 3.8%; p=0.047). Sarcopenic and nonsarcopenic patients had no difference in 
30-day morbidity (8.5% versus 8.5%; p=0.991) or mortality (3.7% versus 0.9%; p=0.07). 
Univariate analysis demonstrated age, sarcopenia, myosteatosis, CCI, and BMI to be associated 
with long-term survival. There was no correlation between BMI and sarcopenia. Both sarcopenia 
and myosteatosis resulted in decreased one-, three-, and five-year survivals compared to their 
counterparts. On multivariate analysis sarcopenia is independently associated with survival, 
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conferring a 1.6-fold increase in death (p=0.04). The combination of sarcopenia plus myosteatosis 
doubled the risk of death compared to sarcopenia alone.
Conclusions—This is the first study to demonstrate that over half of all patients undergoing 
AAA repair are sarcopenic, a condition associated with increased mortality. Sarcopenia with 
myosteatosis is associated with double the mortality of sarcopenia alone. CT scan, but not BMI, 
accurately identifies sarcopenia and myosteatosis. Defining the mechanisms through which 
sarcopenia contributes to late death after AAA repair is critical to developing novel interventions 
that may improve survival in this high risk population.
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Introduction
The primary focus in improving survival in patients with abdominal aortic aneurysms 
(AAA) has been centered on the timing of surgical repair to prevent the catastrophic 
consequences of aneurysm rupture. Intensive population based studies have provided 
detailed guidelines for intervention that rely on factors associated with risk of rupture that 
include maximal transverse diameter, growth rate, aneurysm morphology, and symptoms (1). 
While these efforts have had a significant impact in decreasing complications from rupture, 
assessing mid- and long-term outcomes post AAA repair has largely been ignored (2–5).
In recent years, body composition has emerged as a novel prognostic indicator in both 
malignant and non-malignant diseases (6–8). Sarcopenia, or low muscle mass for height, is a 
catabolic state associated with an inflammatory condition(9). Futhermore, sarcopenia has 
been associated with increased morbidity and mortality risk following major surgical 
procedures (10). Inflammation has been implicated as a driving mechanism for the 
development of sarcopenia(11). Tumor necrosis factor-alpha (TNF-α), interleukin-1beta 
(IL-1β), and interleukin-6 (IL-6) promote muscle wasting by increasing protein degradation 
and decreasing protein synthesis (12–14). Inflammation has been shown to be associated 
with AAA as well. Microscopic examination of AAA have shown inflammatory cells 
infiltrating the aneurysms (15, 16). In addition, patients with AAA have elevated levels of 
inflammatory cytokines, which in turn, activate matrix metalloproteinases (MMPs) (17–20). 
The activation of MMP favors collagen and elastin degradation leading to aortic wall 
weakening and aneurysm formation(20).
Cross-sectional skeletal muscle and adipose tissue masses at the level of the third lumbar 
(L3) vertebrae have been shown to correlate with overall body measurements of each tissue 
types (21). Using specifically designed software body composition measurements can be 
readily obtained from computed tomography (CT) scans that are a standard part of the pre-
operative evaluation for patients undergoing endovascular or open AAA repair. Thus, body 
composition may be a predictor of post-AAA morbidity and mortality.
Herein, we evaluated the impact of body composition on short- and long-term outcomes 
after AAA repair. We hypothesize that patients with sarcopenia, determined by CT derived 
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L3 skeletal muscle measurements at the time of AAA repair, will have increased surgical 
complications and decreased post-operative survival when controlling for other factors. 
Based upon data examining 505 patients undergoing elective and urgent AAA repair at 
Indiana University (IU) we demonstrate that the presence of sarcopenia is a significant 
predictor of survival at five years post-AAA repair.
Methods
This study was approved by the Indiana University Institutional Review Board and carried 
out in compliance with the IU Standard Operating Procedures for Research Involving 
Human Subjects and therefore have been performed in accordance to the ethical standards 
laid down in the 1964 Declaration of Helsinki and its later ammendments.
Selection of patients is outlined in Figure 1. All patients presenting to Indiana University 
Methodist Hospital between January 1, 2012 and July 30, 2015 and the Richard L. 
Roudebush Veterns Administration Medical Center (RRVAMC) between July 1, 2005 and 
July 30, 2015 for repair of AAA were eligible for inclusion. Patients from RRVAMC were 
obtained through a query of the electronic medical record (EMR). The Vascular Quality 
Initiative database was used to obtain patients from IU Methodist Hospital. Together these 
searches identified seven hundred forty-two total patients. One hundred eight did not meet 
inclusion criteria. One hundred twenty-nine patients were excluded for the following 
reasons: sixty-six had no available CT scan, thirty-nine had CT scan of inadequate quality 
for analysis, sixteen had corrupted CT files that could not be analyzed, and eight had 
incomplete clinical data.
Body composition analysis was performed on five-hundred five patients using Slice-O-
Matic® software Version 4.3 (Tomovision, Montreal, Quebec, Canada) by the following 
method: cross-sectional area (cm2) was measured and recorded for skeletal muscle (SKM), 
visceral adipose tissue (VAT), subcutaneous adipose tissue (SCAT), and mean skeletal 
muscle density (SKM HU) at the level of the third lumbar vertebrae (L3)(21). Hounsfield 
thresholds were set at −29 to +50 for SKM, −50 to −150 for VAT, and −30 to −190 for 
SCAT. Two consecutive images were analyzed and the mean of the two images were 
normalized to height in meters squared to establish tissue specific indices (cm2/m2). Total 
muscle measurements included rectus abdominus, external and internal oblique, transversus 
abdominus, psoas, erector spinae, and quadratus lumborum.
Sarcopenia was defined as skeletal muscle index (SKMI) <52.4 cm2/m2 for males and <38.5 
cm2/m2 for females (22). Myosteatosis was defined as mean skeletal muscle density <33 HU 
for patients with body mass index (BMI) ≥25 kg/m2 and <41 HU for patients with BMI <25 
kg/m2 (6). BMI classification was based on the World Health Organization (WHO) 
definitions (23). Patients meeting the criteria for sarcopenia and obesity were classified as 
having sarcopenic obesity. Complications were defined as any deviation from normal 
recovery including the need for a procedural intervention within 30 days of the index 
operation.
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Statistical Analysis
The primary outcome measured was overall survival calculated from the time of surgery to 
the time of death or last follow up. The main prognostic factor was presence of pre-operative 
sarcopenia, however secondary prognostic factors included age, sex, AAA diameter, pre-
operative myosteatosis, BMI classification, and CCI. Age and AAA diameter were treated as 
continuous variables for Cox proportional models. CCI was divided into the following three 
categories: ≤3, 4–5, and ≥6 for Kaplan-Meier and Cox proportional models. Sarcopenia, 
myosteatosis, and sex were treated as categorical variables for Kaplan-Meier and Cox 
proportional models. Kaplan-Meier analyses are reported as median survival in months with 
log-based p values. Cox proportional models are reported as hazard ratios with 95% 
confidence intervals with p values.
Mean age, BMI, SKMI, SKM HU, AAA, and estimated blood loss (EBL) were compared 
between sarcopenic and non-sarcopenic groups by independent t-test. Sex, repair method, 
myosteatosis, complications (overall), race, and rupture were compared between groups 
using Pearson’s chi-squared test. CCI and American Society of Anesthesiologist (ASA) 
score were compared between groups using Mann-Whitney U test. SKMI measurements 
between BMI categories were compared by sex by ANOVA. All p values are two-sided.
Multivariate analysis was performed using Cox proportional models. All variables found to 
be significantly associated with survival on univariate analysis were included in the model. 
Two models were created; one which included BMI and excluded sarcopenia and 
myosteatosis while the second model included sarcopenia and myosteatosis and excluded 
BMI. Two models were required due to the BMI’s dependence on body composition. 
Sarcopenia and myosteatosis are classifications of body composition. BMI is therefore 
influenced by sarcopenia and myosteatosis status. All variables in a multivariate model must 
be independent or the model will not be accurate, thus the need for two models. Age and 
CCI were treated as a continuous variable for both models. BMI was treated as a categorical 
variable and was categorized by WHO classification.
All statistical analyses were performed using IBM SPSS Statistics for Windows version 23.0 
(Chicago, IL). Images for Kaplan-Meier curves and graphs were created using GraphPad 
Prism version 7 (GraphPad software, La Jolla, CA). Significance was set at p<0.05 for all 
results.
Results
Baseline patient characteristics are summarized in Table 1. Using values of sarcopenia 
determined for cancer patients (22), we observed that 58.2% of patients had sarcopenia 
compared to 41.2% without. Sarcopenic patients were older (71.8±8.3 vs. 66.8±8.1 years; 
p<0.001), had larger AAA diameter (60.6±14.0 vs. 57.8±11.7 mm; p=0.01), increased 
comorbidities (32.3% vs. 25.1% CCI ≥6; p=0.03), and increased rates of rupture (8.2% vs. 
3.8%; p=0.05) than non-sarcopenic patients. With regards to body composition analyses 
sarcopenic patients had lower BMI (26.3±5.2 vs. 31.5±5.9 kg/m2; p<0.001), lower SKMI 
(43.7±6.7 vs. 58.7±8.3 cm2/m2; p<0.001), less dense skeletal muscle (28.5±11.1 vs. 
33.0±7.1 HU; p<0.001), and higher rates of myosteatosis (84.4% vs. 52.1%; p<0.001). 
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There was no difference in 30-day post-operative morbidity rate (8.5% vs. 8.5%; p=0.99) or 
30-day post-operative mortality rate (0.9% vs. 3.7%; p=0.07) between patients with 
sarcopenia and those without sarcopenia.
Univariate Kaplan-Meier survival analysis showed that sarcopenic patients had significantly 
decreased overall survival from non-sarcopenic patients (Figure 2A), along with decreased 
one, three, and five-year survivals (Figure 2B). Patients with myosteatosis also had 
significantly decreased overall survival than patients without myosteatosis (Figure 2C) and 
decreased one, three, and five-year survivals (Figure 2D).
Univariate Cox proportional modeling showed increasing age, sarcopenia, myosteatosis, 
increasing CCI, and BMI to each be associated with increased risk of mortality (Table 2). 
Multivariate model 1 showed sarcopenia and increasing CCI to be independently associated 
with increased risk of mortality (Table 2, Model 1). Sarcopenia had the greatest influence on 
mortality in this model carrying a 1.6 fold increased risk of death (Table 2, Model 1). 
Furthermore, sarcopenia was identified in eighty-four of the one-hundred fifteen patient 
deaths, representing 73% of deaths (Figure 3A), while myosteatosis was identified in ninety-
four, or 82%, of all patient deaths (Figure 3B). Patients with sarcopenia plus myosteatosis 
had shorter overall survival than patients with sarcopenia alone or myosteatosis alone 
(Figure 3C). In fact, the combination of sarcopenia plus myosteatosis doubled mortality 
(Figure 3D). Multivariate model 2 (Table 2, Model 2) showed increasing age, increasing 
CCI, and BMI classification of underweight to be significantly associated with increased 
mortality, while BMI classification of overweight was associated with decreased mortality.
Kaplan-Meier survival analysis comparing obese patients with sarcopenia (sarcopenic 
obesity) to obese patients without sarcopenia shows significant difference in survival (Figure 
4A). Cox proportional modeling show sarcopenic obesity confers a 3.5 fold increased risk of 
mortality compared to patients with nonsarcopenic obese patients (HR=3.5; 95% CI=1.6–
7.9).
Mean BMI for patients with sarcopenia is significantly lower than those without sarcopenia 
(26.3 vs. 31.5 kg/m2)(Figure 4B). SKMI measurements were compared among BMI 
categories for both males (Figure 4C) and females (Figure 4D). All BMI categories had 
significantly different SKMI measurements for both sexes. Furthermore, 87.1%, 64.9%, and 
34% of males in the normal, overweight, and obese BMI categories had SKMI 
measurements that qualified as sarcopenic, while 85.7% and 37.5% of females in the normal 
and overweight BMI categories had SKMI measurements which qualified as sarcopenic. 
Overall, 85.7% of underweight, 86.9% of normal, 62.6% of overweight, and 33.3% of obese 
BMI patients had SKMI measurements that fell into the sarcopenic category.
Discussion
According to the Society of Vascular Surgeons (SVS), approximately 200,000 individuals 
will be diagnosed with abdominal aortic aneurysms each year, and 40,000 endovascular and 
open repairs are performed annually to prevent rupture (24). This study identifies 
sarcopenia, a condition of abnormally low skeletal muscle mass, to be an independent 
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predictor of mortality after AAA repair. Sarcopenic patients were found to have decreased 
one, three, and five-year survival compared to non-sarcopenic patients, and was present in 
73% of all deaths. More alarming was the fact that the combination of sarcopenia with 
myosteatosis doubled the mortality over sarcopenia alone.
The current study is the largest, most comprehensive study specifically examining body 
composition and outcomes after AAA repair. There is a growing body of literature on the 
negative effect of sarcopenia on surgical outcomes and mortality. Both Lee et al. and Drudi 
et al. demonstrated increased risk of mortality after AAA repair with decreasing total psoas 
muscle (25, 26). However, both studies defined sarcopenia based on the lowest tertile within 
the study group, making their definition susceptible to selection bias. Our study uses an 
established, validated, sex-specific definition of sarcopenia which did not rely on the current 
patient population being studied, thus eliminating any selection bias (22). The results, 
however, are consistent with Lee et al. and Drudi et al. We establish sarcopenia is a major 
prognostic indicator for patients who have undergone AAA repair, but does not appear to 
influence 30-day outcomes. The data provides sex-specific values that clinicians can use 
clinically to identify patients with sarcopenia that are at high risk of death following 
successful repair. This study also identifies the combination of sarcopenia plus myosteatosis 
as a significant risk factor, doubling the risk of mortality after AAA repair compared to 
sarcopenia alone.
The presence of sarcopenia is a risk factor independent of other known risk factors in AAA 
patients. Age, congestive heart failure, cerebral vascular disease, and diabetes mellitus have 
all been shown to increase the risk of mortality after AAA repair (27). This study, which 
included congestive heart failure, cerebral vascular disease and diabetes mellitus by proxy 
by utilizing the CCI, found that sarcopenia had significant, independent association with 
mortality by multivariate analysis.
Based on these results, any evaluation of a patient for AAA repair should monitor for 
sarcopenia and myosteatosis, as well as the other clinical factors that have been associated 
with poor outcomes. Targeting these patients, ideally before, and surely after AAA repair, 
may prove to be beneficial, thus the mechanisms mediating death in these patients need to be 
elucidated to aid in developing methods to reduce the risk.
A second significant finding is related to obesity and sarcopenia. Obesity has been reported 
to increase the risk of mortality after AAA repair; however, the data herein contradict these 
previous findings (28). A break down of SKMI measurements by BMI category showed that 
BMI is not an accurate reflection of lean body mass, specifically the absence or presence of 
sarcopenia. The majority of patients with normal BMIs (87%) and overweight BMIs (63%) 
met the criteria for sarcopenia. Even patients with BMI’s that categorize them as obese had 
33% rate of meeting the criteria for sarcopenia. Further comparison showed obese patients 
with sarcopenia had significantly decreased survival than obese patients without sarcopenia. 
This suggests that lower rates of sarcopenia are the reason that obesity had a protective 
effect in this study and further demonstrates the adverse effects of sarcopenia. These data 
suggest abandoning BMI as a useful measure for AAA patients in lieu of sarcopenia 
measurements.
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Only twenty-two percent of patients did not have sarcopenia, myosteatosis, or a combination 
of the two. The high rate of muscle abnormalities among all patients in this study suggests 
disruption of normal muscle metabolism in patients with AAA that is associated with death 
and is strikingly similar to the patterns of cachexia seen in cancer patients. While it has been 
shown in certain populations that muscle mass and function can be improved with exercise 
and supplemental protein, the muscle wasting in cancer cachexia, by definition, is resistant 
to reversal by conventional nutritional support (29–31). Several cytokines have been linked 
to the muscle wasting seen in cancer cachexia including tumor necrosis factor-alpha (TNF-
α), interleukin (IL)-1, IL-6, and interferon-gamma (IFN-γ) (32–38). TNF-α, IL-1β, IL-6, 
and IFN-γ are produced by AAA (39,40). Patients with AAA have also been shown to have 
elevated circulatory serum levels of TNF-α, IL-1β, IL-6 and these cytokines have been 
implicated in the pathogenesis of AAA (17, 39). During repair the aneurysmal tissue is not 
excised, and like cancer, may act as a non-healing wound, continuing to drive inflammation 
and production of cachexia-associated cytokines. This study highlights the importance of 
identifying the mechanism and correcting the muscle metabolism disruption in AAA 
patients. This hopefully may result in significantly increased long-term survival after repair.
While this is the largest, most comprehensive study of its kind, there are still some 
limitations. This is a single-institution, retrospective study, and although the results should 
be generalizable due to the magnitude of the cohort, the cohort was largely male Caucasians; 
application of the results to females and minorities populations should be done with caution. 
There was also an age difference between the sarcopenic and non-sarcopenic groups. The 
authors do not believe this to be a limitation, however, because when controlling for age in 
the multivariate analysis sarcopenia remained a significant negative prognostic factor.
For various reasons, thirty-two percent (237/742) of patients who presented to the institution 
for AAA repair were not able to be included in the study. It would be unlikely that inclusion 
of these patients would have a significant effect on the results, as the patient cohort of five-
hundred five patients still represents a very large patient population. The authors believe that 
inclusion of these patients would only strengthen the results observed.
Despite these limitations, this study demonstrates sarcopenia as a common comorbidity in 
AAA patients undergoing repair that is independently associated with long-term all-cause 
mortality. It is imperative for sarcopenia to be integrated into all patient evaluations prior to 
open or endovascular AAA repair. The presence of sarcopenia should not exclude a patient 
from undergoing repair of an AAA, but rather be used to identify a subset of patients who 
are vulnerable to poor outcomes. Sarcopenic patients may benefit from pre- and post-
operative interventions targeted at improving muscle mass and quality.
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